Related Experiment Video
Updated: Jul 5, 2026
Detection of Nuclear Blebbing and DNA Leakage in Mammalian Cells by Immunofluorescence
Published on: January 17, 2025
The molecular and cellular defects underlying Pelizaeus-Merzbacher disease
1Western Diagnostic Pathology, 74 McCoy Street, Myaree, WA 6154, Australia. Karen.Woodward@symbionhealth.com
Abstract:
Pelizaeus-Merzbacher disease (PMD) is a recessive X-linked dysmyelinating disorder of the central nervous system (CNS). The most frequent cause of PMD is a genomic duplication of chromosome Xq22 including the region encoding the dosage-sensitive proteolipid protein 1 (PLP1) gene. The PLP1 duplications are heterogeneous in size, unlike duplications causing many other genomic disorders, and arise by a distinct molecular mechanism. Other causes of PMD include PLP1 deletions, triplications and point mutations. Mutations in the PLP1 gene can also give rise to spastic paraplegia type 2 (SPG2), an allelic form of the disease. Thus, there is a spectrum of CNS disorder from mild SPG2 to severe connatal PMD. PLP1 encodes a major protein in CNS myelin and is abundantly expressed in oligodendrocytes, the myelinating cells of the CNS. Significant advances in our understanding of PMD have been achieved by investigating mutant PLP1 in PMD patients, animal models and in vitro studies. How the different PLP1 mutations and dosage effects give rise to PMD is being revealed. Interestingly, the underlying causes of pathogenesis are distinct for each of the different genetic abnormalities. This article reviews the genetics of PMD and summarises the current knowledge of causative molecular and cellular mechanisms.
Insights
Pelizaeus-Merzbacher disease (PMD) is an X-linked disorder affecting central nervous system (CNS) myelin. Genetic mutations in the proteolipid protein 1 (PLP1) gene cause a spectrum of PMD and SPG2, with distinct pathogenic mechanisms.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked recessive disorder impacting central nervous system (CNS) myelin development.
- The primary cause is genomic duplication of the PLP1 gene region on chromosome Xq22, leading to dosage sensitivity.
- Other genetic abnormalities, including PLP1 deletions, triplications, and point mutations, also cause PMD and allelic spastic paraplegia type 2 (SPG2).
Purpose of the Study:
- To review the genetic basis of PMD.
- To summarize current knowledge on the molecular and cellular mechanisms underlying PMD pathogenesis.
- To elucidate the spectrum of CNS disorders arising from PLP1 gene mutations.
Main Methods:
- Review of existing literature on PMD genetics.
- Analysis of studies involving mutant PLP1 in patients, animal models, and in vitro systems.
- Synthesis of findings on molecular and cellular mechanisms of pathogenesis.
Main Results:
- PLP1 gene mutations and dosage effects are central to PMD and SPG2.
- PLP1 duplications are heterogeneous in size and arise via a unique mechanism.
- Pathogenesis differs significantly across various genetic abnormalities of PLP1.
- A spectrum of disease severity exists, from mild SPG2 to severe congenital PMD.
Conclusions:
- Understanding PLP1 gene mutations is crucial for diagnosing and potentially treating PMD and related disorders.
- Distinct molecular mechanisms underlie the pathogenesis of different PLP1 genetic abnormalities.
- Further research into PLP1 function and mutation effects will advance therapeutic strategies for dysmyelinating disorders.
Related Concept Videos
01:20Inborn Errors of Metabolism
01:27Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...